Elevation Oncology Stock Gross Profit

ELEV Stock

USD 0.61 0.03 5.17%

Elevation Oncology fundamentals help investors to digest information that contributes to Elevation Oncology's financial success or failures. It also enables traders to predict the movement of Elevation Stock. The fundamental analysis module provides a way to measure Elevation Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elevation Oncology stock.

		Last Reported	Projected for Next Year
	Gross Profit	-39 K	-41 K

Gross Profit is likely to drop to about (41 K) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Elevation Oncology Company Gross Profit Analysis

Elevation Oncology's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Current Elevation Oncology Gross Profit

(41.0K)

Most of Elevation Oncology's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elevation Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Elevation Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Elevation Oncology is extremely important. It helps to project a fair market value of Elevation Stock properly, considering its historical fundamentals such as Gross Profit. Since Elevation Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Elevation Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Elevation Oncology's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Long Term Debt Total	Capital Surpluse
Total Assets		0.85	0.85	-0.8	-0.71	0.74	0.51	0.87	1.0	1.0	0.15	0.41	0.55	0.37	-0.42	-0.42
Total Stockholder Equity	0.85		1.0	-0.72	-0.58	0.5	-0.02	0.98	0.85	0.85	-0.03	0.34	0.43	0.27	-0.32	-0.32
Net Tangible Assets	0.85	1.0		-0.72	-0.58	0.5	-0.02	0.98	0.85	0.85	-0.04	0.34	0.43	0.25	-0.31	-0.31
Net Debt	-0.8	-0.72	-0.72		0.17	-0.74	-0.38	-0.63	-0.81	-0.82	0.34	0.0	0.02	0.0	0.0	0.0
Retained Earnings	-0.71	-0.58	-0.58	0.17		-0.26	-0.36	-0.72	-0.71	-0.7	-0.53	-0.79	-0.93	-0.68	0.78	0.78
Accounts Payable	0.74	0.5	0.5	-0.74	-0.26		0.64	0.51	0.75	0.72	0.28	-0.18	0.22	-0.16	0.18	0.18
Total Liab	0.51	-0.02	-0.02	-0.38	-0.36	0.64		0.06	0.51	0.5	0.32	0.19	0.33	0.16	-0.18	-0.18
Net Invested Capital	0.87	0.98	0.98	-0.63	-0.72	0.51	0.06		0.87	0.87	0.13	0.46	0.6	0.32	-0.4	-0.4
Total Current Assets	1.0	0.85	0.85	-0.81	-0.71	0.75	0.51	0.87		1.0	0.15	0.41	0.55	0.37	-0.42	-0.42
Net Working Capital	1.0	0.85	0.85	-0.82	-0.7	0.72	0.5	0.87	1.0		0.1	0.42	0.53	0.37	-0.43	-0.43
Intangible Assets	0.15	-0.03	-0.04	0.34	-0.53	0.28	0.32	0.13	0.15	0.1		0.11	0.64	0.23	-0.22	-0.22
Common Stock	0.41	0.34	0.34	0.0	-0.79	-0.18	0.19	0.46	0.41	0.42	0.11		0.78	0.55	-0.75	-0.75
Property Plant Equipment	0.55	0.43	0.43	0.02	-0.93	0.22	0.33	0.6	0.55	0.53	0.64	0.78		0.43	-0.59	-0.59
Long Term Debt	0.37	0.27	0.25	0.0	-0.68	-0.16	0.16	0.32	0.37	0.37	0.23	0.55	0.43		-0.96	-0.96
Long Term Debt Total	-0.42	-0.32	-0.31	0.0	0.78	0.18	-0.18	-0.4	-0.42	-0.43	-0.22	-0.75	-0.59	-0.96		1.0
Capital Surpluse	-0.42	-0.32	-0.31	0.0	0.78	0.18	-0.18	-0.4	-0.42	-0.43	-0.22	-0.75	-0.59	-0.96	1.0

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Elevation Oncology

Gross Profit Over Time

Did you try this?

Run Headlines Timeline Now

Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

All Next

Launch Module

Elevation Fundamentals

	Return On Equity	-0.64
	Return On Asset	-0.25
	Current Valuation	(37.69 M)
	Shares Outstanding	59.12 M
	Shares Owned By Insiders	0.20 %
	Shares Owned By Institutions	77.96 %
	Number Of Shares Shorted	6.21 M
	Price To Earning	0.16 X
	Price To Book	0.50 X
	EBITDA	(41.47 M)
	Net Income	(45.7 M)
	Cash And Equivalents	122.54 M
	Cash Per Share	5.26 X
	Total Debt	30.14 M
	Current Ratio	6.48 X
	Book Value Per Share	1.17 X
	Cash Flow From Operations	(56.18 M)
	Short Ratio	9.36 X
	Earnings Per Share	(0.80) X
	Target Price	7.0
	Number Of Employees	29
	Beta	1.25
	Market Capitalization	34.35 M
	Total Asset	89.09 M
	Retained Earnings	(195.97 M)
	Working Capital	83.82 M
	Net Asset	89.09 M

About Elevation Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Elevation Stock Analysis

When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC